|
|
Colony Stimulating Factors - Current Market Dynamics & Future OutlookPublished by: AS Insights Published: Dec. 1, 2004 - 54 Pages Table of Contents1. Executive Briefing 2. State of the Science 2.1 Overview 2.1.1 Definitions & Scope 2.1.2 The Process of Hematopoiesis 2.1.2 Structure, Production & Function 2.1.2.1 Filgrastim 2.1.2.2 Peg-Filgrastim 2.2 Clinical Applications of Colony Stimulating Factors 2.2.1 Role of Colony Stimulating Factors in Neutropenia 2.2.2 Role of Colony Stimulating Factors in Chemotherapy Treated Cancer Patients 2.2.3 Role of Colony Stimulating Factors in Radiology Treated Cancer Patients 3. Market Size & Growth Rates 3.1 The World Market for Colony Stimulating Factors 3.2 The North American Market for Colony Stimulating Factors 3.3 The European Markets for Colony Stimulating Factors 3.4 The Japanese Market for Colony Stimulating Factors 4. Leading Brands on the Market 4.1 Overview 4.2 Leading Brands Revenue & Market Share 4.3 Profiles of Leading Brands 4.3.1 Neulasta (Peg-Filgrastim) 4.3.2 Neupogen (Filgrastim) 4.3.3 Neutrogin / Granocyte (Lenograstim) 4.3.4 Gran (Filgrastim) 4.3.5 Proleukin (Aldesleukin) 4.3.6 Leukine (Sargramostim) 4.3.7 Other Brands on the Market 4.4 Dosage & Formulations 4.4.1 Neulasta 4.4.2 Neupogen 4.5 Decision Making & Dispensing Dynamics 4.6 Present Pricing Strategy 4.7 Reimbursement Status 4.8 Key Patents Expiry Dates 4.8.1 Filgrastim Key Patents Expiry Dates 4.8.2 Peg-Filgrastim Key Patents Expiry Dates 5. Leading Participants in the Colony Stimulating Factors Market 5.1 Overview 5.2 Leading Participants Market Shares 5.3 Profiles of Leading Participants 5.3.1 Amgen 5.3.2 Roche 5.3.3 Schering 5.4 Other Participants in the Market 5.4.1 Chugai 5.4.2 Chiron 5.4.3 Kirin 5.4.4 GeneMedix 5.4.5 Dragon Pharmaceuticals 5.4.6 CIGB-HEBER 5.5 Potential New Entrants Into the Market 5.5.1 Novartis / Sandoz 5.5.2 Ratiopharm / BioGeneriX 5.5.2 Affymax 5.6 Country Based Colony Stimulating Factors Production Initiatives 5.6.1 India 5.6.2 China 5.6.3 Cuba 6. Strategic Opportunities 6.1 Market Attractiveness 6.2 Opportunities in New Product Development 6.3 Opportunities in Product Synergy 6.4 Opportunities in Super Generics 7. The Shape of the Market to Come 7.1 Main Vectors of Change 7.1.1 Patient Pool Trends 7.1.2 Product Pricing Trends 7.2 Current & Potential Future Generic Entries 7.3 Colony Stimulating Factors Market Forecasts (2005 - 2010) 7.4 The Market in 2010 List of Tables & Figures 1. The World Market for Colony Stimulating Factors - Market Revenue & Growth Rates (1994 - 2004) 2. North American Market for Colony Stimulating Factors - Market Revenue & Growth Rates (1994 - 2004) 3. European Market for Colony Stimulating Factors - Market Revenue & Growth Rates (1994 - 2004) 4. Japanese Market for Colony Stimulating Factors - Market Revenue & Growth Rates (1994 - 2004) 5. Colony Stimulating Factors - Leading Brands Revenue (2004) 6. Colony Stimulating Factors - Leading Brands Market Shares (2004) 7. Neulasta - Global Revenue & Growth Rates (2001 - 2004) 8. Neupogen - Global Revenue & Growth Rates (1994 - 2004) 9. Neutrogin / Granocyte, Lenograstim - Global Revenue & Growth Rates (1994 - 2004) 10. Proleukin (Aldesleukin) Global Revenue & Growth Rates (1998 - 2004) 11. Leukine (Sargramostim) - Global Revenue & Growth Rates (1994 - 2004) 13. Filgrastim key patents expiry dates 14. Peg-Filgrastim key patents expiry dates 15. Leading Companies Market Shares 16. Colony Stimulating Factors Global Market - Revenue & Growth Rates Forecasts (2005 - 2010) AbstractBy the end of 2004 the world market for Colony Stimulating Factors was valued at $3.6 billion, a growth of 11% over 2003. The market has been growing at an average annual growth rate of 16% over the previous 5 years.Amgen's Neupogen (Filgrastim) will lose its key patent in major markets in 2006 opening the market for generics. Amgen is already preparing itself for this major patent loss by concentrating its marketing efforts on Neulasta (Peg-Filgrastim) its once-per-cycle long acting pegylated product and by offering little or no support to Neupogen. Many generic companies have already synthesized and tested own filgrastim products and are ready to launch their products in major markets once patent is expired. Many licensing opportunities are available and possibilities of a super generic are there. Colony Stimulating Factors, Current Market Dynamics & Future Outlook is a timely strategic consulting report from ASInsights assessing both the technology status and the competitive landscape of Colony Stimulating Factors and Interleukin-2 markets. The report examines both the US, the European and the Japanese markets. It profiles leading products and companies and offer revenue forecasts to the year 2010.
The report also assesses market attractiveness, the potential for generic entries and for the first time, gives profiles of CSFs production initiatives in developing countries like Cuba, China and India.
|
|
|||
|
About MarketResearch.com
|
||||